Slide 1: The LEGACY Study Results
THE LEGACY STUDY RESULTS 1 © 2022 Boston Scientific Corporation or its affiliates. All rights reserved. PI-880304-AA
Slide 2: LEGACY Primary Study Objectives
LEGACY Primary Study Objectives The LEGACY STUDY: To assess the local tumor control AND duration of response following treatment with TheraSphere Y-90 glass microspheres used as either: 1. neoadjuvant to transplantation or resection OR 2. stand-alone in patients with unresectable, solitary lesion HC
Slide 3: LEGACY Study Design
LEGACY Study Design 3 independent US sites with highly reproducible results of high ablative dose to tumor in patients that met study criteria demonstrating a low recurrence rate in Early and Advanced HCC Consecutively treated Y-90 glass microsphere patients • Between January 2014 and December 2017
Slide 4: LEGACY Study Baseline Characteristics
LEGACY Study Baseline Characteristics Treated Population Treated Population Patient Characteristics (N=162) Treatment Characteristics (N=162) N (%) N (%) Median age (range), years 66 (21-90) Median Tumor Size (range), cm 2.6 (0.9-8.1) ≥ 18 to < 65 69 (42.6) Initial Y90 Treatment Goal ≥ 65 to < 75 64
Slide 5: LEGACY is a robust multicenter study of TheraSphere as neoadjuvant or standalone therapy
LEGACY is a robust multicenter study that evaluated TheraSphere™ as a Neoadjuvant or Standalone Therapy in Treating Primary Liver Cancer (HCC) HIGHLIGHT DURABLE TheraSphere patients treated as a destination TUMOR CONTROL IN EARLY therapy compared favorably to those receiving & ADVANCED HCC transplan
Slide 6: Radiation Segmentectomy
Radiation Segmentectomy Long-term outcomes demonstrated a median overall survival of 6.7 years suggesting radiation segmentectomy should be the preferred treatment approach when possible in unresectable HCC patients Radiation segmentectomy is a proven Overall Survival for All Patients with TheraSphe
Slide 7: Time to Event Outcomes (Treated Population)
Time to Event Outcomes (Treated Population) Time to Progression with TheraSphere Glass Y- Progression-Free Survival with TheraSphere Glass 90 Microspheres Y-90 Microspheres % patients without localized tumor progression at 24 M % Patients alive and Progression-free at 24 M Localized mRECIST 100.0% L
Slide 8: The LEGACY Study Summary
The LEGACY Study Summary TheraSphere glass Y-90 treatment resulted in: • 88.3% ORR (best response): 84.0% CR and 4.3% PR (localized mRECIST) • High perfused volume absorbed dose (median 410 Gy) was well tolerated and effective as a selective ablative treatment • 96.8% achieved their best respon
Slide 9: © 2022 Boston Scientific Corporation or its affiliates. All rights reserved. PI-880304-AA
9 © 2022 Boston Scientific Corporation or its affiliates. All rights reserved. PI-880304-AA
Slide 10: Important Information
Important Information Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third- party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presen
Slide 11: Important Information
Important Information TheraSphere™ Yttrium-90 Glass Microspheres INDICATION FOR USE: TheraSphere is indicated for use as selective internal radiation therapy (SIRT) for local tumor control of solitary tumors (1-8 cm in diameter), in patients with unresectable hepatocellular carcinoma (HCC), Child- P